Related Experiment Video
Updated: Jun 23, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Beyond viral suppression: combining PEG-interferon with novel immunotherapies for functional cure of chronic
Qi Wang1,2, Wen Deng1,2, Shiyu Wang1,2
1Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Abstract:
Chronic hepatitis B (CHB) affects approximately 250 million people worldwide. The major barrier to cure lies in the persistent presence of covalently closed circular DNA (cccDNA) and integrated HBV DNA within hepatocytes, which continuously drive hepatitis B surface antigen (HBsAg) expression and maintain immune tolerance, thereby leading to functional exhaustion of antiviral effector cells. Although nucleos(t)ide analogues (NAs) effectively suppress viral replication, they have limited impact on cccDNA activity and antigen production. In contrast, pegylated interferon-α (PEG-IFN-α) enhances antigen presentation, activates innate immunity, and partially restores HBV-specific T cell function, thereby contributing to the disruption of immune tolerance to some extent. However, its therapeutic efficacy remains influenced by host immune status and antigen burden. With the development of antigen-reduction strategies (such as siRNA/antisense oligonucleotides [ASO] and HBsAg-targeting monoclonal antibodies), therapeutic vaccines, and immune-modulatory approaches, PEG-IFN-α is increasingly being incorporated into combination therapies. This review summarizes its immunological basis and clinical advances, and further discusses biomarker-driven patient stratification strategies, with the aim of improving functional cure rates in CHB.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release
Retrovirus Life Cycles
